The last 18 months has demonstrated that it’s now more important than ever to ignore short-term volatility and instead focus on the long-term prospects of a business.

There are no better examples of that thinking than these two S&P/ASX 200 Index (ASX: XJO) examples, which Seneca Financial Solutions investment advisor Arthur Garipoli rates as buys:

‘Positive view’ on health devices giant

Healthcare is one of those industries that don’t fare too badly even through times of economic stress.

That’s because people will, understandably, prioritise their physical and mental wellbeing over other goods and services.

As such, a leader in its field like Resmed CDI (ASX: RMD) makes a sensible buy.

“This manufacturer of medical devices for respiratory disorders recently reported results that beat market expectations,” Garipoli told The Bull.

“Revenue of US$1.0337 billion for the three months ending on December 31, 2022 was up 16% on the prior corresponding period.”

The hardware company did encounter some roadblocks to growth last year as a global computer chip shortage hampered its own production.

But that short-term issue, Garipoli feels, is now past it.

“We retain a positive view on RedMed, given an improving supply chain,” he said.

“It will enable ResMed to meet additional demand for respiratory units, leading to revenue growth.”

The ResMed share price is 8.9% up over the past year.

Excellent dividend yield plus cheap share price

Deterra Royalties Ltd (ASX: DRR) is a mining royalty company, meaning it’s almost like a landlord collecting rent from sites where resource companies are operating.

This model has some advantages over directly owning mining shares, according to Garipoli.

“Deterra holds a 1.232% royalty in BHP Group Ltd (ASX: BHP)’s Mining Area C (MAC) involving iron ore operations in the Pilbara region of Western Australia,” he said.

“It gives Deterra price and volume exposure to a world class asset without taking on mining risk.”

Garipoli noted that the first half update showed BHP increasing production at the MAC site.

“We believe the stock is undervalued due to the quality of the asset, its discount to peers and providing investors with a forecast fully franked dividend yield of 6.6%.”

The Deterra share price has remained flat over the past year and so far in 2023.

The post 2 ‘undervalued’ ASX 200 shares to ‘beat market’ before everyone else wakes up appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• These world-class ASX 200 growth shares are buys according to brokers
• Capital deities and destroyers: The best and worst at putting money to work among ASX 200 shares
• CSL shares dip despite new FDA approval
• ‘Resilient earnings’: Buy 3 ASX 200 shares to win through troubled times

Motley Fool contributor Tony Yoo has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/aljbhF2

• Stock Market